Harmony Biosciences price target raised to $52 from $42 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Harmony Biosciences to $52 from $42 and keeps an Outperform rating on the shares following last week’s “very successful” investor day. The firm incorporated revenue contributions from EPX-100 in Dravet and Lennox-Gastaut syndromes. It believes Harmony” is on the cusp of a significant company transformation” and sees “multiple reasons” for the stock to move higher over the next 12-24 months.